Archives: Research
Research & Insights Content Type
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
-
Abandon Biosimilars as Biologics are Natural Monopolies
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
-
List Price, Net Price, and the Rebate Caught in the Middle
-
Overview of Original Subscription Model and Features of LA and WA Proposals
-
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
-
Expansion of the Medicare 340B Payment Program
-
The “Netflix Model” of Financing Hepatitis C Treatment
-
Cardiovascular Drugs Not Price Aligned with Value in US
-
Perspective on National Coverage Analysis of CAR-T Therapies